The Use of Long-Acting Injectable Antipsychotics in Schizophrenia: Evaluating the Evidence
The DOI matches its Crossref record, with a small difference in title or year; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Long-acting injectable antipsychotics (LAIs) are among the most effective treatments in psychiatry, yet they remain underutilized in clinical practice. Although LAIs are typically used to maintain treatment adherence in patients with chronic schizophrenia, recent research has suggested that they may also provide an effective treatment strategy for patients with early-phase or first-episode disease. In October 2015, a group of 8 experts on the management of schizophrenia and LAIs met to evaluate the evidence surrounding the efficacy, safety, and cost-effectiveness of LAIs and to develop practical recommendations regarding the clinical use, education, and unmet needs related to LAIs. Participants were also asked to rate the importance of several patient characteristics when choosing an LAI versus an oral antipsychotic, from the perspectives of 4 different stakeholder groups: patients, health care professionals, families, and payers. The evidence review demonstrated that LAIs are superior to placebo for acute and maintenance treatment of schizophrenia and, in general, appear to be similar to one another in terms of schizophrenia relapse prevention. Study design impacts the demonstrated efficacy of LAIs versus oral antipsychotics, but recent database and randomized controlled studies favor the use of LAIs in early-phase schizophrenia patients. LAIs vary considerably in their propensity to cause certain adverse effects, including weight gain, metabolic effects, extrapyramidal symptoms, and prolactin elevation, and these differences can be used to help guide LAI selection. Some studies, but not all, have demonstrated significant reductions in health care utilization or overall costs with LAIs. The expert panel identified several barriers to LAI use in current practice, including clinician lack of knowledge, negative attitudes about LAIs, and resource and cost issues. The participants also identified a number of additional factors that should be considered when weighing the use of LAI therapy, including medication adherence, relapse risk and severity, cognitive impairment, ease of use, substance misuse, access and cost, stigma, social support, patient autonomy, control over medication dosing, fear of needles, and the potential for patient harm due to relapses and associated loss of functioning. This evidence review, discussion, and summary recommendations may help clinicians, patients, families, payers, and other stakeholders to better characterize the role of LAIs in the treatment of schizophrenia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition to the benefits of reduced treatment gaps with LAI versus oral antipsychotics, studies, particularly those in real-world samples, have demonstrated reduced psychopathology, relapses, hospitalizations, and mortality risk with LAI formulations [98–104].”
From Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview (2021) · cites this paper as [100]
In the citing paper
“Longacting injectable antipsychotics can enhance adherence, 10 but surveys of physician attitudes about LAIs show that they consider LAIs primarily for patients who have already had repeated hospitalizations and relapses.11”
From Effect of Long-Acting Injectable Antipsychotics vs Usual Care on Time to First Hospitalization in Early-Phase Schizophrenia: A Randomized Clinical Trial (2020) · cites this paper as [10]
In the citing paper
“Currently, a number of studies have proven the effectiveness, safety and tolerability of LAIs [25]”
From The role of shared decision-making in improving adherence to pharmacological treatments in patients with schizophrenia: A clinical review (2020) · cites this paper as [25]
Citations
Cites
The publisher hasn’t deposited this paper’s reference list.
Cited by
Items 101–200 of 372
Hieronymus, F., Correll, C. U., & Østergaard, S. D. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02491-6 · Cited by 26
Self-citationFond, G. B., Falissard, B., Nuss, P., Collin, C., Duret, S., Rabbani, M., Chefdebien, I. D., Tonelli, I., Llorca, P., & Boyer, L. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02154-4 · Cited by 20
Aripiprazole Lauroxil: A Review in Schizophrenia
Frampton, J. E. (2017) · Drugs · doi:10.1007/s40265-017-0848-4 · Cited by 21
Changes in attitude towards LAI antipsychotic maintenance treatment: A two-year follow-up study
Pietrini, F., D’Anna, G., Tatini, L., Talamba, G. A., Andrisano, C., Calderani, E., Manetti, M., Prodi, P. R., Ricca, V., & Ballerini, A. (2018) · European Psychiatry · doi:10.1016/j.eurpsy.2018.06.002 · Cited by 23
Citrome, L., Belcher, E. D., Stacy, S., Suett, M., Mychaskiw, M., & Salinas, G. D. (2022) · Patient Preference and Adherence · doi:10.2147/ppa.s326290 · Cited by 23
Self-citationSi, T., Li, N., Lu, H., Cai, S., Zhuo, J., Correll, C. U., Zhang, L., & Feng, Y. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118772449 · Cited by 20
Self-citationIwata, N., Inagaki, A., Sano, H., Niidome, K., Kojima, Y., & Yamada, S. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01396-w · Cited by 18
Fung, K. P.-L., Liu, J. J. W., Sin, R., Bender, A., Shakya, Y., Butt, N., & Wong, J. P.-H. (2022) · Ethnicity & Health · doi:10.1080/13557858.2019.1640350 · Cited by 17
Stone, J., Roux, S., Taylor, D., & Morrison, P. (2018) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125318795130 · Cited by 21
Fitzgerald, H. M., Shepherd, J., Bailey, H. M. L., Berry, M., Wright, J., & Chen, M. (2021) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s330936 · Cited by 27
Carrascal-Laso, L., Franco, M., Berrocal, B. G., Marcos-Vadillo, E., Sánchez-Iglesias, S., Lorenzo, C., Sánchez-Martín, A., Ramos-Gallego, I., García-Salgado, M. J., & Isidoro‐García, M. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10040289 · Cited by 16
Lin, D., Pilon, D., Zhdanava, M., Joshi, K., Lafeuille, M., Côté‐Sergent, A., Vermette-Laforme, M., & Lefèbvre, P. (2021) · Current Medical Research and Opinion · doi:10.1080/03007995.2021.1882412 · Cited by 16
Li, P., Benson, C. J., Geng, Z., Seo, S., Patel, C. A., & Doshi, J. A. (2023) · Journal of Medical Economics · doi:10.1080/13696998.2023.2189859 · Cited by 16
Early use of long‐acting injectable antipsychotics in bipolar disorder type I: An expert consensus
Vieta, E., Tohen, M. F., McIntosh, D., Kessing, L. V., Sajatovic, M., & McIntyre, R. S. (2024) · Bipolar Disorders · doi:10.1111/bdi.13498 · Cited by 21
Correll, C. U., Shi, L., Weiss, C., Hobart, M., Eramo, A., Duffy, R. A., Weiller, E., & Baker, R. A. (2019) · CNS Spectrums · doi:10.1017/s1092852918001086 · Cited by 16
“LAI antipsychotics were stopped abruptly prior to brexpiprazole initiation, which, due to the long half-lives of LAIs, can be equated to cross-titration.(18,19) Antipsychotic switching may be complicated by potential pharmacodynamic and pharmacokinetic withdrawal and rebound phenomena when switching from a highly anti…”
BackgroundSelf-citationAntipsychotiques à Action Prolongée: Révision de l’algorithme QAAPAPLE
Stip, É., Abdel‐Baki, A., Roy, M., Bloom, D., & Grignon, S. (2019) · The Canadian Journal of Psychiatry · doi:10.1177/0706743719847193 · Cited by 22
Lauriello, J., Weiden, P. J., Gleeson, C. D., Shah, A., Boulanger, L., Jariwala‐Parikh, K., Hedgeman, E., & O’Sullivan, A. K. (2021) · CNS Drugs · doi:10.1007/s40263-021-00849-2 · Cited by 15
Self-citationLong-Acting Injectable Antiretroviral Agents for HIV Treatment and Prevention
Ys, K. (2021) · Infection and Chemotherapy · doi:10.3947/ic.2021.0136 · Cited by 20
Grover, S., Sahoo, S., & Mehra, A. (2019) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001109 · Cited by 17
Bartoli, F., Ostuzzi, G., Crocamo, C., Corbo, M., D’Agostino, A., Martinotti, G., Ostinelli, E. G., Tabacchi, T., Barbui, C., & Carrà, G. (2020) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000317 · Cited by 15
Yan, T., Greene, M., Chang, E. Y., Hartry, A., Touya, M., & Broder, M. S. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1395733 · Cited by 16
Lin, C., Chan, H., Hsu, C., & Chen, F.-C. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.10.023 · Cited by 16
Long-acting injectable antipsychotics for the treatment of schizophrenia in Spain
Arango, C., Baeza, I., Bernardo, M., Cañas, F., de Dios, C., Díaz‐Marsá, M., García‐Portilla, M. P., Gutiérrez-Rojas, L., Olivares, J. M., Rico‐Villademoros, F., et al. (2019) · Revista de Psiquiatría y Salud Mental (English Edition) · doi:10.1016/j.rpsmen.2018.03.004 · Cited by 25
Guideline for pharmacological treatment of schizophrenia 2022
Japanese Society of Neuropsychopharmacology (2024) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12497 · Cited by 20
Gorwood, P. A. P. M., Yıldırım, M., Madera‐McDonough, J., Fagiolini, A. M., Arango, C., Correll, C. U., Arcà, E., Barlassina, A., Selveindran, S. M., Sahota, N., et al. (2025) · BMC Psychiatry · doi:10.1186/s12888-025-06725-3 · Cited by 14
Self-citationKane, J. M., Eshet, R., Harary, E., Tohami, O., Elgart, A., Knebel, H., Sharon, N. A., Suett, M., Franzenburg, K. R., Davis, G. L., et al. (2024) · CNS Drugs · doi:10.1007/s40263-024-01102-2 · Cited by 14
Self-citationPharmakotherapie der Schizophrenie
Correll, C. U. (2020) · Der Nervenarzt · doi:10.1007/s00115-019-00858-z · Cited by 19
Self-citationAuxilia, A. M., Buoli, M., Caldiroli, A., Carnevali, G. S., Tringali, A. G. M., Nava, R., Clerici, M., & Capuzzi, E. (2023) · Biomedicines · doi:10.3390/biomedicines11020314 · Cited by 16
Safety and Efficacy of Aripiprazole 2-Month Ready-to-Use 960 mg
Citrome, L., Such, P., Yıldırım, M., Madera‐McDonough, J., Beckham, C., Zhang, Z., Larsen, F., & Harlin, M. (2023) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.23m14873 · Cited by 14
Self-citationZhang, H., Turkoz, I., Zhuo, J., Mathews, M., Tan, W., & Feng, Y. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0638-0 · Cited by 15
Si, T., Zhuo, J., Turkoz, I., Mathews, M., Tan, W., & Feng, Y. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1401608 · Cited by 15
Paliperidone palmitate once‐every‐3‐months in adults with early illness schizophrenia
Lynum, K. S. B., Turkoz, I., & Kim, E. (2018) · Early Intervention in Psychiatry · doi:10.1111/eip.12685 · Cited by 14
Miron, A. A., Petric, P. S., Teodorescu, A., Ifteni, P. I., Chele, G. E., & Szalontay, A. S. (2023) · Brain Sciences · doi:10.3390/brainsci13020173 · Cited by 17
Ma, N., Zhang, L., Zhang, W., He, Y., Ye, C., & Li, X. (2023) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s413371 · Cited by 19
Chen, W. J., Wu, C.-S., Liu, C., Kuo, P., Chan, H., Lin, Y., Chung, Y.-C. E., & Chen, W. J. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.17006 · Cited by 15
Correll, C. U., Johnston, K., Turkoz, I., Gray, J., Sun, L. L., Doring, M., & Sajatovic, M. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.21495 · Cited by 21
Self-citationPelizza, L., Maestri, D., Paulillo, G., & Pellegrini, P. (2021) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001495 · Cited by 16
Miranda, J. J. F., Díaz-Fernández, S., & Lopez-Munoz, F. J. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12071101 · Cited by 13
Miron, A. A., Ifteni, P. I., Teodorescu, A., & Petric, P. S. (2022) · Healthcare · doi:10.3390/healthcare10071265 · Cited by 16
Rubio, J. M., Guinart, D., Kane, J. M., & Correll, C. U. (2023) · CNS Drugs · doi:10.1007/s40263-023-01009-4 · Cited by 13
Self-citationMcIntyre, R. S., Such, P., Yildirim, M., Madera‐McDonough, J., Zhang, Z., Larsen, F., & Harlin, M. (2023) · Current Medical Research and Opinion · doi:10.1080/03007995.2023.2219155 · Cited by 13
Kane, J. M., Agid, O., Castle, D. J., Citrome, L., Fagiolini, A. M., Kishimoto, T., Larrauri, C. A., Leucht, S., Rubio, J. M., Sajatovic, M., et al. (2025) · Neurology and Therapy · doi:10.1007/s40120-025-00838-3 · Cited by 20
Self-citationTakács, P., Kunovszki, P., Timtschenko, V., Fehér, L., Balázs, T., Hegyi, R., Czobor, P., & Bitter, I. (2022) · Schizophrenia Bulletin Open · doi:10.1093/schizbullopen/sgac013 · Cited by 12
Schöttle, D., Clerzius, G., Janetzky, W., Oluboka, O. J., Roy, M., Therrien, F., & Wiedemann, K. (2022) · European Psychiatry · doi:10.1192/j.eurpsy.2022.27 · Cited by 11
Vita, A., Fagiolini, A. M., Maina, G., Mencacci, C., Spina, E., & Galderisi, S. (2023) · Annals of General Psychiatry · doi:10.1186/s12991-022-00430-1 · Cited by 14
Li, P., Geng, Z., Benson, C. J., Patel, C. A., & Doshi, J. A. (2025) · Advances in Therapy · doi:10.1007/s12325-024-03075-6 · Cited by 18
García‐Portilla, M. P., Ruiz, A. B., Robina, F. G., Dorado, M. G., & Rengel, P. M. L. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.2023496 · Cited by 12
Litman, R. E., Naber, D., Anta, L., Martínez, J., Filts, Y., & Correll, C. U. (2023) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s392351 · Cited by 14
Self-citationLi, N., Feng, Y., Lu, H., Cai, S. L., Zhuo, J., Si, T., & Zhang, L. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s158353 · Cited by 12
Use of Long-Acting Injectable Antipsychotic in an Inpatient Unit of a Community Teaching Hospital
Olayinka, O. O., Oyelakin, A., Cherukupally, K., Virk, I., Ojimba, C., Khadka, S., Maksymenko, A., Fouron, P., Khandaker, T., Olupona, T., et al. (2019) · Psychiatry Journal · doi:10.1155/2019/8629030 · Cited by 13
Khoury, A. C. E., Pilon, D., Morrison, L., Shak, N., Llaneza, A. J., Kim, E., & Lefèbvre, P. (2020) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2020.26.2.176 · Cited by 14
Miranda, J. J. F., Díaz-Fernández, S., & Lopez-Munoz, F. J. (2021) · The Journal of Nervous and Mental Disease · doi:10.1097/nmd.0000000000001299 · Cited by 15
Díaz-Fernández, S., Frías-Ortiz, D. F., & Miranda, J. J. F. (2022) · Revista de Psiquiatría y Salud Mental (English Edition) · doi:10.1016/j.rpsmen.2022.01.002 · Cited by 13
The place of long-acting injectable antipsychotics in the treatment of schizophrenia
Kane, J. M., & Rubio, J. M. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231157219 · Cited by 14
Self-citationLi, Q., Li, X. R., Ye, C., Jia, M., & Si, T. (2023) · CNS Drugs · doi:10.1007/s40263-023-01028-1 · Cited by 12
Correll, C. U., Brieden, A., & Janetzky, W. (2023) · Schizophrenia · doi:10.1038/s41537-023-00405-5 · Cited by 19
Self-citationTurkoz, I., Daskiran, M., Siddiqui, U., Knight, R. K., Johnston, K. L., & Correll, C. U. (2024) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyad067 · Cited by 15
Self-citationLopez, A., & Rey, J. A. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s140383 · Cited by 13
Antipsychotic Use in Early Pregnancy and the Risk of Maternal and Neonatal Complications
Lin, H., Lin, F., Katz, A. J., Wang, I., & Wu, C. (2022) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2022.04.006 · Cited by 30
Cicala, G., de Filippis, R., Barbieri, M. A., Cutroneo, P. M., Fazio, P. D., Schoretsanitis, G., & Spina, E. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1130636 · Cited by 13
Antipsychotic-like effects of a novel phosphodiesterase 10A inhibitor T-251 in rodents
Takakuwa, M., Watanabe, Y., Tanaka, K., Ishii, T., Kagaya, K., Taniguchi, H., Kotera, J., & Hashimoto, K. (2019) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2019.172757 · Cited by 11
Liu, J., Wang, Q., Su, L., Yang, L., Zou, L., & Bai, L. (2022) · BMC Psychiatry · doi:10.1186/s12888-022-03728-2 · Cited by 11
The Gut Microbiome and Treatment-Resistance in Schizophrenia
Seeman, M. V. (2019) · Psychiatric Quarterly · doi:10.1007/s11126-019-09695-4 · Cited by 14
How do we select an antipsychotic for those with schizophrenia?
Faden, J. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1674284 · Cited by 12
Bramante, S., Salvo, G. D., Maina, G., & Rosso, G. (2023) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s374696 · Cited by 9
Correll, C. U., Arango, C., Fagiolini, A. M., Giordano, G. M., Leucht, S., & de Pablo, G. S. (2024) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s459450 · Cited by 10
Self-citationRisperidone ISM ® : review and update of its usefulness in all phases of schizophrenia
Messer, T., Bernardo, M., Anta, L., & Martínez, J. (2024) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253241280046 · Cited by 12
Correll, C. U. (2025) · CNS Spectrums · doi:10.1017/s1092852925100503 · Cited by 15
Self-citationJackson, J. W., Fulchino, L. A., Rogers, J. R., Mogun, H., Polinski, J. M., Henderson, D. C., Schneeweiß, S., & Fischer, M. A. (2017) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4354 · Cited by 10
Barlati, S., Nibbio, G., Bianchi, F. P., Gigli, E. B. L., Calzavara‐Pinton, I., Cerati, C., Fiori, J., Lisoni, J., Deste, G., & Vita, A. (2022) · Psychiatry Research · doi:10.1016/j.psychres.2022.114878 · Cited by 13
Pesa, J. A., Liu, Z., Fu, A. Z., Campbell, A. K., & Grucza, R. A. (2023) · Schizophrenia Research · doi:10.1016/j.schres.2023.09.033 · Cited by 10
Basu, A., Benson, C. J., & Alphs, L. D. (2018) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2018.24.8.759 · Cited by 12
Risk factors for readmission among a cohort of psychiatric inpatients in Lilongwe, Malawi
Barnett, B. S., Kusunzi, V., Magola, L., Borba, C. P. C., Udedi, M. M., Kulisewa, K., & Hosseinipour, M. C. (2019) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2019.1699116 · Cited by 12
Patel, R. S., & Tankersley, W. E. (2021) · CNS Spectrums · doi:10.1017/s109285292100050x · Cited by 12
Pietrini, F., Tatini, L., Santarelli, G., Brugnolo, D., Squillace, M., Bozza, B., Ballerini, A., Ricca, V., & D’Anna, G. (2021) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2021.1912358 · Cited by 12
Gentile, S. (2017) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2017-0004 · Cited by 12
Llácer, J. M. B., Martínez-Hortelano, A., & Albelda, B. R. (2019) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2019.1576905 · Cited by 11
Cost Reductions Associated With Long-Acting Injectable Antipsychotics According to Patient Age
Stip, É. (2017) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.16lr11402 · Cited by 9
Lin, T.-C., & Lin, C. (2023) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyad053 · Cited by 10
Zhu, T.-T., Liu, P., Hashimoto, K., & Yang, J. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03603-6 · Cited by 14
Aripiprazole Lauroxil Dosing Regimens: Understanding Dosage Strengths and Injection Intervals
Sommi, R. W., Rege, B., Wehr, A. Y., FALDU, S. P., Du, Y., & Weiden, P. J. (2020) · CNS Spectrums · doi:10.1017/s1092852920002072 · Cited by 9
Tatini, L., D’Anna, G., Pietrini, F., Calligaris, E., Ballerini, A., & Ricca, V. (2021) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000359 · Cited by 10
Doshi, J. A., Li, P., Geng, Z., Seo, S., Patel, C. A., & Benson, C. J. (2023) · Psychiatric Services · doi:10.1176/appi.ps.20230142 · Cited by 9
Patel, C. A., Khoury, A. E., Huang, A., Wang, L., & Bashyal, R. (2020) · Current Therapeutic Research · doi:10.1016/j.curtheres.2020.100587 · Cited by 9
Suetani, S., Siskind, D. J., Phillipou, A., Waterreus, A. J., Morgan, V. A., & Castle, D. J. (2021) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674211009602 · Cited by 9
Miranda, J. J. F., Díaz-Fernández, S., & Lopez-Munoz, F. J. (2022) · Biomedicines · doi:10.3390/biomedicines11010042 · Cited by 13
Mood disorders and somatic comorbidities
Serretti, A. (2024) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000562 · Cited by 9
Correll, C. U., Rubio, J. M., Citrome, L., Mychaskiw, M. A., Thompson, S., Franzenburg, K. R., Suett, M., Kotak, S. V., & Kane, J. M. (2024) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s477674 · Cited by 8
Self-citationDíaz-Fernández, S., López-Muñoz, F., & Fernández-Miranda, J. J. (2021) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000581 · Cited by 10
D’Anna, G., Rotella, F., Santarelli, G., Scannerini, S., Fanelli, A., Ricca, V., & Ballerini, A. (2022) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000990 · Cited by 9
Lin, C., Chan, H., Wang, F., & Hsu, C. (2022) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253221079165 · Cited by 10
Turkoz, I., Wong, J. G. X., Chee, B., Siddiqui, U., Knight, R. K., Richarz, U., & Correll, C. U. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231200258 · Cited by 10
Self-citationEthnic and Age Disparities in Patients Taking Long-acting Injectable Atypical Antipsychotics
Soleman, M., Lam, N. H., & Woo, B. K. P. (2017) · Cureus · doi:10.7759/cureus.1772 · Cited by 8
Hodgson, R. E. (2019) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s191198 · Cited by 10
Noel, J. M., & Jackson, C. W. (2020) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaa303 · Cited by 9
Schizophrenia and Related Psychoses
(2021) · Wiley eBooks · doi:10.1002/9781119870203.mpg001 · Cited by 9
Pharmacokinetic characteristics of risperidone ISM for the treatment of schizophrenia
Schoretsanitis, G., & Correll, C. U. (2025) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2025.2474126 · Cited by 8
Self-citationDo antipsychotics work in people with schizophrenia? A review of outcomes and effect sizes
Correll, C. U. (2025) · CNS Spectrums · doi:10.1017/s1092852925100461 · Cited by 10
Self-citationFranzenburg, K. R., Hansen, R., Suett, M., Yaari, A., Sergerie, M., Levin, A. P., Kaplan, S., Gonzalez, A., Sedigh, K., Heres, S., et al. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1645328 · Cited by 9
Oluboka, O. J., Clerzius, G., Janetzky, W., Schöttle, D., Therrien, F., Wiedemann, K., & Roy, M. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-04893-8 · Cited by 7
Metadata
- Authors
- Correll, C. U., Citrome, L., Haddad, P. M., Lauriello, J., Olfson, M., Calloway, S. M., & Kane, J. M.
- Affiliations
- Hofstra University (US)
- New York Medical College (US)
- University of Manchester (GB)
- University of Missouri (US)
- Columbia University (US)
- Missouri Department of Social Services (US)
- Northwell Health (US)
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2016-09-30
- Volume
- 77
- Issue
- Suppl 3
- Pages
- 1-24
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2527103551
- Cited by
- 372
- References
- 0
- Citations by year
- 2026: 28 · 2025: 36 · 2024: 37 · 2023: 54 · 2022: 40 · 2021: 50 · 2020: 36 · 2019: 49 · 2018: 22 · 2017: 20
- FWCI
- 27.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
- Social Sciences › Psychology › Clinical Psychology › Family Caregiving in Mental Illness
- Keywords
- long-acting injectable antipsychotics, schizophrenia, first-episode schizophrenia, medication adherence, relapse prevention, cost-effectiveness, adverse effects, weight gain, metabolic effects, extrapyramidal symptoms, prolactin elevation, stakeholder perspectives, clinical guidelines
- MeSH terms
- Chronic Disease, Cost-Benefit Analysis, Delayed-Action Preparations, Humans, Injections, Intramuscular, Mental Health Services, Schizophrenia, Schizophrenic Psychology, Antipsychotic Agents, Utilization Review, Randomized Controlled Trials as Topic, Treatment Outcome, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.